CX3CR1 and B-cell non-Hodgkin lymphoma: Based on suppression of host anti-tumor immunity mediated by CD11b+CX3CR1+ monocytes in solid cancer models [15–17] and the upregulation of CX3CR1 receptor in various types of B-cell lymphoma including DLBCL [18], we hypothesized that CD11b+CX3CR1+ monocytes might influence the prognosis of patients with DLBCL by promoting angiogenesis and immunosuppression within the tumor microenvironment.